1. Пинхасов Б.Б., Лутов Ю.В., Деев Д.А., Селятицкая В.Г. Стратификация риска развития и тяжести метаболического синдрома у пациентов терапевтического профиля // Клин. медицина. 2017. 95. (5). 412–418.
2. Ройтберг Г.Е., Дорош Ж.В., Шархун О.О. Влияние инсулинорезистентности на формирование и прогрессирование компонентов метаболического синдрома (итоги пятилетнего исследования) // Рац. фармакотерапия в кардиологии. 2015. 11. (2). 132–138.
3. Свеклина Т.С., Таланцева М.С., Барсуков А.В. Метаболический синдром и воспаление: актуальные вопросы патогенеза // Клин. лаб. диагностика. 2013. (3). 7–10.
4. Цанава И.А., Шаронова Л.А., Вербовой А.Ф. Метаболический синдром и сердечно-сосудистые заболевания // Рус. мед. журн. 2017. 25. (11). 785–789.
5. Alberti K.G.M.M., Eckel R.H., Grundy S.M. et al. Harmonizing the Metabolic Syndrome/ A Joint Interim statement of the International Diabetes Federation taskforce on epidemiology and prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009. 120. 1640–1645.
6. Amato M.C., Giordano C., Galia M., Criscimanna A., Vitabile S., Midiri M., Galluzzo A. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk // Diabetes Care. 2010. 33. (4). 920–922.
7. Amato M.C., Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction // Int. J. Endocrinol. 2014. ID 730827.
8. Amato M.C., Pizzolanti G., Torregrossa V., Misiano G., Milano S., Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes // PLoS One. 2014. 9. (3). ID e91969.
9. Beltran-Sanchez H., Harhay M.O., Harhay M.M., Mc Elligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010 // J. Am. Coll. Cardiol. 2013. 62. (8). 697–703.
10. Constantinopoulos P., Michalaki M., Kottorou A., Habeos I., Psyrogiannis A., Kalfarentzos F., Kyriazopoulou V. Cortisol in tissue and systemic level as a contributing factor to the development of metabolic syndrome in severely obese patients // Eur. J. Endocrinol. 2015. 172. (1). 69–78.
11. Du T., Yuan G., Zhang M., Zhou X., Sun X., Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance // Cardiovasc. Diabetol. 2014. 13. ID 146.
12. Du T., Sun X., Huo R., Yu X. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009 // Int. J. Obesity. 2014. 38. 840–847.
13. Ebrahimi F., Christ-Crain M. Metabolic syndrome and hypogonadism – two peas in a pod // Swiss Med. Wkly. 2016. 146. ID w14283.
14. Grundy S.M. Metabolic syndrome update // Trends Cardiovasc. Med. 2016. 26. (4). 364–373.
15. Hatzimouratidis K., Hatzichristou D. Testosterone and erectile function: an unresolved enigma // Eur. Urol. 2007. 52. (1). 26–28.
16. Kang Y.M., Jung C.H., Cho Y.K., Jang J.E., Hwang J.Y., Kim E.H., Lee W.J., Park J.Y., Kim H.K. Visceral adiposity index predicts the conversion of metabolically healthy obesity to an unhealthy phenotype // PLoS One. 2017. 12.(6). e0179635. 14 p.
17. Lorenzo C., Williams K., Hunt K.J., Haffner S.M. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes // Diabetes Care. 2007. 30. (1). 8–13.
18. Matthews D., Hosker J., Rudenski A. Homeostatis model assessment: insulin resistance and b-cell functionn from fasting plasma glucose and insulin concentrations in man // Diabetologia. 1985. 28. 412–419.
19. Moretti C., Lanzolla G., Moretti M., Gnessi L., Carmina E. Androgens and hypertension in men and women: a unifying view // Curr. Hypertens. Rep. 2017. 19. ID 44.
20. Novikova E., Selyatitskaya V., Mitrofanov I., Pinkhasov B., Karapetyan A. Association of erectile dysfunction and hypogonadism with metabolic syndrome in men with lower urinary tract symptoms of younger and older age groups // Adv. Sex. Med. 2014. 4. 55–64.
21. Paniagua J.A. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome // World J. Diabetes. 2016. 7. (19). 483–514.
22. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline // J. Clin. Endocrinol. Metab. 2008. 93. (10). 3671–3689.
23. Ruan H., Dong L.Q. Adiponectin signaling and function in insulin target tissues // J. Mol. Cell. Biol. 2016. 8. (2). 101–109.
24. Reaven G.M. The individual components of metabolic syndrome: is there a raison d’etre? // J. Am. Nutr. 2007. 26.(3). 191–195.
25. Research letter. Visceral adipose tissue dysfunction and mortality among a population-based sample of males and females // Diabetes Metab. 2016. 42. 382–385.
26. Varlamov O. Western-style diet, sex steroids and metabolism // Biochim. Biophys. Acta. 2017. 1863. 1147–1155.
27. Wang N., Zhai H., Han B., Li Q., Chen Y., Xia F., Lin D., Lu Y. Visceral fat dysfunction is positively associated with hypogonadism in Chinese men // Scientific Reports. 2016. 6. ID 19844.
28. Xiao J., Shen C., Chu M.J., Gao Y.X., Xu G.F., Huang J.P., Xu Q.Q., Cai H. Physical activity and sedentary behavior associated with components of metabolic syndrome among people in rural China // PLoS One. 2016. 11.(1). ID e0147062.
